Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome

Reduction of APL antibodies by immunoadsorption may be a lifesaving therapy for the management of DAH with high titer of APL antibodies. Autologous HSCT may be a valid treatment option in patients with primary APS and no response to standard immunosuppressive therapy.

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Angelillo-Scherrer, Anne, Mansouri Taleghani, Behrouz, Förger, Frauke, Baerlocher, Gabriela M., Pabst, Thomas, Pöllinger, Alexander, Banz, Yara, Geiser, Thomas, Kremer Hovinga, Johanna A., Rovó, Alicia
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Exceptional Case Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737408/
https://ncbi.nlm.nih.gov/pubmed/31506284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000465
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍